Syneron Medical Stock Rating Lowered by Zacks (ELOS)
Syneron Medical (NASDAQ:ELOS) was downgraded by Zacks to a “neutral” rating in a research note issued on Wednesday. They currently have a $10.80 target price on the stock. Zacks‘s price objective would indicate a potential upside of 2.18% from the company’s current price.
Syneron Medical (NASDAQ:ELOS) traded down 0.28% on Wednesday, hitting $10.53. The stock had a trading volume of 18,865 shares. Syneron Medical has a 52 week low of $8.04 and a 52 week high of $13.32. The stock has a 50-day moving average of $10.00 and a 200-day moving average of $10.74. The company has a market cap of $386.1 million and a price-to-earnings ratio of 57.08.
Syneron Medical (NASDAQ:ELOS) last released its earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.07. The company had revenue of $64.60 million for the quarter, compared to the consensus estimate of $63.52 million. During the same quarter last year, the company posted $0.02 earnings per share. Syneron Medical’s revenue was down 6.1% compared to the same quarter last year. Analysts expect that Syneron Medical will post $0.25 EPS for the current fiscal year.
Syneron Medical Ltd. designs, develops and markets aesthetic medical products based on its various technologies including its Electro-Optical Synergy (NASDAQ:ELOS), technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.